What's happened?
Amplia Therapeutics Limited (ASX: ATX) has appointed the Nucleus Network in Melbourne to conduct its upcoming Phase 1 clinical trial testing AMP945, the Company’s proprietary Focal Adhesion Kinase inhibitor (FAKi).
What are the key highlights?
- The Phase-1 trial will enrol up to 64 healthy volunteers and aims to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AMP945 when given as single and multiple doses.
- By conducting the trial in healthy volunteers, data from the trial may be used to support Phase 2 clinical trials for multiple diseases including various solid cancers and fibrotic diseases such as idiopathic pulmonary fibrosis.
- The company expects data from the Phase 1 trial to be available in the first half of 2021.
For further information, please refer to the announcement linked below.
